Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients

Abstract

Metabolic syndrome (MetS) is characterized by abdominal obesity, hyperglycaemia, dyslipidaemia and hypertension. FTO gene has been implicated in the pathogenesis of obesity, but the available scientific data concerning their relationship to antipsychotic druginduced obesity and metabolic syndrome is still incomplete and inconsistent, which indicates that continuing the investigation of this gene's role is necessary. Patients and Methods: In the present study, 517 patients with schizophrenia underwent antipsychotic drug treatment, and two groups were identified: patients with MetS and without MetS. Genotyping of 6 SNPs in the FTO gene was performed, and the results analyzed using R-programme. Results: We performed a statistical analysis to identify possible associations of the frequencies of genotypes and alleles of the studied polymorphisms with the presence of metabolic syndrome in schizophrenia patients, with the presence of abdominal obesity, and with an increased body mass index. The rs7185735 polymorphism did not meet the Hardy-Weinberg criterion and was excluded. After correcting for differences in age, gender and duration of illnesses, none of the variants was shown to be related to metabolic syndrome or abdominal obesity, but rs9939609, rs1421085, rs3751812 and rs8050136 were associated with body mass index. Conclusion:The present study provides additional support for these SNP's roles as a pharmacogenetic biomarker that may become useful in the framework of the personalized medicine approach.

Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study

“…Costa-Dookhan and Kalinowska et al [ 15 , 19 ] have found that the obesity rate of schizophrenia patients is as high as 77.2%, of which 71.6% is male and 85.6% is female, which is 4 to 5 times that of the general population. Although different countries may have different definitions and measurement methods for obesity, they have all obtained consistent results that both outpatients and inpatients with schizophrenia generally have a higher incidence of obesity [ 20 , 21 ]. Therefore, the obesity problem of schizophrenia patients has aroused the attention of mental health workers.…”

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome

“…We recruited 517 patients with schizophrenia from different psychiatric clinics of the Siberian region in the Russian Federation. The detailed characteristics of the studied group are presented in Boiko et al (2021) [41]. The informed consent of all participants was obtained.…”

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia

“…It is, therefore, highly desirable to discover biomarkers that can be used to detect specific sensitivities to certain adverse effects in individual patients. Since 2006, our group has been investigating pharmacogenetic factors associated with the occurrence of adverse effects of antipsychotics, such as dyskinesia [ 9 , 10 , 11 , 12 , 13 ], hyperprolactinemia [ 14 , 15 ], and metabolic syndrome [ 16 , 17 ]. We have looked at various neurotransmitter systems such as glutamate [ 10 , 11 ], dopamine [ 9 , 11 , 15 ], serotonin [ 12 , 14 , 16 ] and acetylcholine [ 13 ].…”